"Arachis" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A plant genus of the family FABACEAE that includes peanuts.
Descriptor ID |
D010367
|
MeSH Number(s) |
B01.650.940.800.575.912.250.401.077
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Arachis".
Below are MeSH descriptors whose meaning is more specific than "Arachis".
This graph shows the total number of publications written about "Arachis" by people in this website by year, and whether "Arachis" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2002 | 0 | 1 | 1 |
2007 | 1 | 0 | 1 |
2008 | 0 | 1 | 1 |
2009 | 1 | 0 | 1 |
2010 | 1 | 1 | 2 |
2011 | 1 | 2 | 3 |
2013 | 1 | 1 | 2 |
2016 | 1 | 1 | 2 |
2017 | 1 | 1 | 2 |
2018 | 2 | 1 | 3 |
2019 | 4 | 1 | 5 |
2020 | 0 | 5 | 5 |
2021 | 2 | 3 | 5 |
2022 | 3 | 2 | 5 |
2023 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Arachis" by people in Profiles.
-
Phase 3 Trial of Epicutaneous Immunotherapy in Toddlers with Peanut Allergy. N Engl J Med. 2023 May 11; 388(19):1755-1766.
-
Food Allergy Management Practices Utilizing Individual Patient Thresholds: A Work Group Report of the AAAAI Adverse Reactions to Foods Committee. J Allergy Clin Immunol Pract. 2023 04; 11(4):1083-1086.e1.
-
Management of Anaphylaxis During Peanut Oral Immunotherapy. Curr Allergy Asthma Rep. 2023 01; 23(1):21-27.
-
Participant characteristics and safety outcomes of peanut oral immunotherapy in the RAMSES and ARC011 trials. Ann Allergy Asthma Immunol. 2022 Dec; 129(6):758-768.e4.
-
Qualitative interviews to understand health care providers' experiences of prescribing licensed peanut oral immunotherapy. BMC Res Notes. 2022 Aug 08; 15(1):273.
-
Reduced pro-inflammatory dendritic cell phenotypes are a potential indicator of successful peanut oral immunotherapy. PLoS One. 2022; 17(5):e0264674.
-
Real-world adoption of FDA-approved peanut oral immunotherapy with palforzia. J Allergy Clin Immunol Pract. 2022 04; 10(4):1120-1122.e1.
-
Maximum Dose Food Challenges Reveal Transient Sustained Unresponsiveness in Peanut Oral Immunotherapy (POIMD Study). J Allergy Clin Immunol Pract. 2022 02; 10(2):566-576.e6.
-
Safety of Epicutaneous Immunotherapy in Peanut-Allergic Children: REALISE Randomized Clinical Trial Results. J Allergy Clin Immunol Pract. 2022 07; 10(7):1864-1873.e10.
-
Memory and na?ve gamma delta regulatory T-cell gene expression in the first 24-weeks of peanut oral immunotherapy. Clin Immunol. 2021 09; 230:108820.